Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AD-104-A (Fenofibrate) in Renal Impairment
NCT05703282Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fenofibrate in hyperlipidemia (4 arms), sponsored by Addpharma, Inc. Primary endpoints: Maximum Plasma Concentration (Cmax) and Area Under the Curve (AUC). Started Mar 2023; status: completed.
02
Drugs
fenofibrate
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05703282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703282.